Analytical Data
-
Gene name
DC
- Application
-
Alternative Names
DC；D2LIC；LIC3；Cytoplasmic dynein 2 light intermediate chain 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TCX1
-
Expression Region
1-352aa
-
AA Sequence
MPSETLWEIAKAEVEKRGINGSEGDGAEIAEKFVFFIGSKNGGKTTIILRCLDRDEPPKPTLALEYTYGRRAKGHNTPKDIAHFWELGGGTSLLDLISIPITGDTLRTFSLVLVLDLSKPNDLWPTMENLLQATKSHVDKVIMKLGKTNAKAVSEMRQKIWNNMPKDHPQDHELIDPFPVPLVIIGSKYDVFQDFESEKRKVICKTLRFVAHYYGASLMFTSKSEALLLKIRGVINQLAFGIDKSKSICVDQNKPLFITAGLDSFGQIGSPPVPENDIGKLHAHSPMELWKKVYEKLFPPKSINTLKDIKDPARDPQYAENEVDEMRIQKDLELEQYKRSSSKSWKQIELDS
-
Molecular Weight
44.8kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Dendritic cell (DC) reprogramming has emerged as a captivating area of study in immunology, focusing on harnessing the unique properties of dendritic cells to enhance immune responses, particularly in cancer therapy and vaccine development. Dendritic cells are pivotal in the initiation and modulation of adaptive immunity, acting as professional antigen-presenting cells that bridge innate and adaptive responses. However, their functionality can be limited by the tumor microenvironment, which often subdues their immunogenic potential. Recent research aims to reprogram these cells, either through genetic engineering or exposure to specific stimuli, to overcome these inhibitory signals. This reprogramming can enhance their ability to present antigens, secrete pro-inflammatory cytokines, and activate T cells more efficiently. Innovative approaches, including the use of fusion proteins, nanoparticles, and other delivery systems, are being explored to optimize the reprogramming process. The potential applications in immunotherapies and vaccines highlight the importance of DC reprogramming in achieving better clinical outcomes in various diseases, particularly in oncology. As such, understanding the molecular mechanisms governing DC function and reprogramming is crucial for developing more effective therapeutic strategies. The ongoing exploration in this field holds significant promise for advancing personalized medicine and improving patient responses to existing therapies.
